Learn from expert faculty what key clinical considerations inform the use of biosimilars in oncology practice with this series of CME/CE/CPE-certified ClinicalThought™ commentaries!
How do biosimilars compare with reference biologics and small-molecule compounds? Here’s my take.
Here’s my take on why some of the key reasons biosimilars may be an attractive cost-cutting measure in cancer care also pose a challenge to their widespread adoption.
Herein, I summarize recent biosimilar approvals as well as how these agents might affect patient care and counseling in oncology practice.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.